| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| ln Vivo |
Perfluoroheptanic acid (0.0015–0.15 mg/kg body weight/day; gavage; once daily; 16 days) can induce reproductive toxicity in male offspring of C57BL/6 mice[1]. Perfluoroheptanic acid (1.25–5% (v/v); transdermal; once daily; for 28 days) can induce systemic toxicity in female B6C3F1 mice in a subchronic 28-day skin exposure model, including increased liver weight, altered immune cell phenotype, hepatocyte hypertrophy, and dysregulation of gene expression related to the PPAR pathway[3].
|
|---|---|
| Animal Protocol |
Animal/Disease Models:C57BL/6 mice (females: mated at 7 weeks of age; male offspring: sacrificed at 7 weeks of age; prenatal exposure reproductive toxicity model) [1]
Doses: 0.0015 mg/kg bw/d; 0.015 mg/kg bw/d; 0.15 mg/kg bw/d Route of Administration: Gavage; daily; 16 days (GD1-GD16) Experimental Results: Sperm count and concentration decreased. The head area of forward motility cells in the 0.015 mg/kg bw/d group was significantly increased. The lumen of the seminiferous tubules in the 0.0015 mg/kg bw/d group was slightly dilated. In the 0.015 mg/kg bw/d group, it led to disordered arrangement of seminiferous epithelium, reduced number of spermatogenic cells and dilation of seminiferous tubule lumen. In the 0.15 mg/kg bw/d group, it caused severe disruption of the seminiferous epithelium, a reduction in the germinal cell layer, and atrophy of the seminiferous tubules. Absolute levels of m6A in testicular tissue were decreased. Mettl3 and Mettl5 expression were decreased, while Mettl14 expression was increased. Pcif1 and Wtap expression were decreased, while Hnrnpa2b1 expression was increased. |
| References |
|
| Molecular Formula |
C7HF13O2
|
|---|---|
| Molecular Weight |
364.06
|
| CAS # |
375-85-9
|
| Appearance |
Colorless to off-white <30°C Solid,>30°C Liquid
|
| SMILES |
O=C(O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
|
| Synonyms |
Perfluoroheptanoic acid; Tridecafluoroheptanoic acid; PFHpA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~274.68 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (13.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of physiological saline: Dissolve 0.9 g of sodium chloride in double-distilled water and dilute to 100 mL to obtain clear physiological saline. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (13.73 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD saline (4°C, store for one week): Dissolve 2 g of SBE-β-CD powder in 10 mL of saline until completely dissolved and clear. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (13.73 mM)(saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7468 mL | 13.7340 mL | 27.4680 mL | |
| 5 mM | 0.5494 mL | 2.7468 mL | 5.4936 mL | |
| 10 mM | 0.2747 mL | 1.3734 mL | 2.7468 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
